Drug Profile
Entecavir - Chong Kun Dang Pharmaceutical
Alternative Names: EntecaBell ODTLatest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator Chong Kun Dang
- Class Antivirals; Cyclopentanes; Hypoxanthines; Small molecules
- Mechanism of Action DNA-directed RNA polymerase inhibitors; RNA-directed DNA polymerase inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis B
Most Recent Events
- 13 Feb 2019 Chemical structure information added
- 01 Oct 2015 Launched for Hepatitis B in South Korea (PO) before October 2015
- 01 Oct 2015 Chong Kun Dang Pharmaceutical initiates enrolment in a phase IV trial for Hepatitis B in South Korea (NCT02588937)